Trexall® / Otrexup®
Low-dose methotrexate is a cornerstone DMARD for rheumatoid arthritis and psoriasis. Anti-inflammatory effects at low doses differ from high-dose oncology mechanism.
| Dosage Form | Oral Tablet / SC Injectable (Autoinjector) |
| Strength | 2.5 mg (oral); 7.5–25 mg/week (SC) |
| Storage | Store at 20–25°C. Protect from light. |
| Category | Immunology |
| Availability | Available for Transfer |
Rheumatoid arthritis; psoriasis (severe, recalcitrant); juvenile idiopathic arthritis; off-label: various autoimmune conditions.
At low doses, primarily increases adenosine release, which has anti-inflammatory effects. Also inhibits aminoimidazole carboxamide ribonucleotide (AICAR) transformylase and mildly inhibits DHFR.
Each Burrard Pharmaceuticals technology transfer package for Methotrexate includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.